Rheumatoid Arthritis News

SAN DIEGO — COVID-19 vaccine boosters led to a significantly increased antibody response in patients using abatacept or TNF inhibitors regardless of whether they held medication, according to data presented at ACR Convergence 2023.

SAN DIEGO — Approximately 75% of patients in rheumatoid arthritis remission who taper TNF inhibitors to withdrawal experience a flare within 3 years, according to data presented at ACR Convergence 2023.

Following HHS’ blockbuster announcement of the first 10 drugs that would be subject to Medicare price negotiations, patients and providers alike have been looking forward to meaningful reductions in their costly treatments.

Among patients with rheumatoid arthritis, the chosen course of therapy does not have an impact on the risk for developing a serious infection, according to data published in Rheumatology.

People who work lower-paid, manual-labor jobs are more likely to discontinue employment in the first 5 years after an early inflammatory arthritis diagnosis, vs. those who work in managerial or professional capacities, according to data.

A Janus kinase inhibitor may preserve beta-cell function for children and young adults recently diagnosed with type 1 diabetes, according to findings published in The New England Journal of Medicine.

SAN DIEGO — TNF inhibitors demonstrate comparable risks for hospitalization and death vs. non-TNF agents in patients with rheumatoid arthritis-associated interstitial lung disease, according to data presented at ACR Convergence 2023.

SAN DIEGO — In this Healio video, Jeffrey A. Sparks, MD, MMSc, highlighted studies from members of his group at Brigham and Women’s Hospital that were presented at ACR Convergence 2023.

SAN DIEGO — In this video, Jeffrey A. Sparks, MD, MMSc, spoke with Healio about the safety of TNF inhibitors compared with alternative targeted therapies for patients with rheumatoid arthritis-associated interstitial lung disease.

Patients receiving the adalimumab biosimilar SB5 demonstrated high persistence, consistent effectiveness and no new safety signals through 48 weeks, according to data published in BioDrugs.